Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.
about
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversalInteraction of Isoflavones with the BCRP/ABCG2 Drug TransporterSmall and Innovative Molecules as New Strategy to Revert MDREZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumorsDevelopment of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalphaInhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to PraziquantelKnocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretionTargeting multidrug resistance in cancerDeterminants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).Assessment of drug transporter function using fluorescent cell imagingEpigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapyQuinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring positionThe epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.Transport in technicolor: mapping ATP-binding cassette transporters in sea urchin embryos.Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).The role of drug efflux pumps in acute myeloid leukemia.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.The challenge of exploiting ABCG2 in the clinic.ABCG2: a perspective.ABC transporters: unvalidated therapeutic targets in cancer and the CNSMBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenograftsEvaluation of (99m)technetium-mebrofenin and (99m)technetium-sestamibi as specific probes for hepatic transport protein function in rat and human hepatocytesBenzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitorStrategies for reversing drug resistance.Breast cancer resistance protein (BCRP) in acute leukemia.PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanismHG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).Alterations in P-Glycoprotein Expression and Function Between Macrophage Subsets.Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.Synthesis of novel 1,8-acridinediones derivatives: Investigation of MDR reversibility on breast cancer cell lines T47D and tamoxifen-resistant T47D.Role of the breast cancer resistance protein (ABCG2) in drug transport.Role of efflux pumps and metabolising enzymes in drug delivery.Role of P-glycoprotein in transplacental transfer of methadoneMetabolism of ATP-binding cassette drug transporter inhibitors: complicating factor for multidrug resistance.Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro.
P2860
Q21246014-60F2E71D-BA6C-4045-806B-4BBB9B5767B3Q26801110-7C865C46-B51E-400B-88C4-CA762A500370Q27012455-D287B0D6-26BE-48BE-969E-CD97134D60A2Q27318449-A63076A4-5E79-4AAB-A864-6B11624442EEQ28394197-B392944D-9624-49EC-B585-78649BE18E77Q28543846-58F2418F-FD15-4386-B8EC-6F5FC3929037Q28570070-E99F3980-083E-4ED9-A034-E64E5E011D76Q29616803-98F9DEEB-C848-497E-BAB1-E93EC4E6EBFCQ30364846-DD36F87B-13CB-4FBE-A284-992554813935Q30571452-76B67CAF-AA43-40CF-830A-BF05E435FEFDQ33357010-B94A6A75-E1FD-415A-A579-B7C8B9E7773AQ33706574-0EF023C1-3F33-433E-8209-35DF7AFEB93BQ33753716-46761F67-BDC3-49B0-B4C1-A8F23A27D283Q34094825-9BB22449-A593-4764-B7CB-2DB964DA45DAQ34173709-EC2211A4-C168-471E-A555-E17994F25C7EQ34176588-2CB55095-926C-46B8-B6AA-E2820FA90765Q34743441-FCC215CF-10B8-4247-9FCE-49657C8509E2Q34769834-7A0D42C6-4060-4975-AEDF-2F5A8659D4B9Q34871636-F1A51720-321B-45F8-A832-A941ECD0C60CQ34968909-C2647AD9-DF23-4875-A83F-FEA0D4D8ABB7Q35016817-5A2E97B1-09EF-4D1B-9551-4712178622D3Q35056738-4F04D840-B7D7-4FBD-9E57-1A24AE6F6C38Q35068041-E4C8320E-B9D7-4FBF-B440-F2391F922325Q35086354-EBAE04B0-BCCD-49F5-AA3F-2BC26E02F3CBQ35181940-A4FE386A-17CF-4FFE-84DA-E7BB00209757Q35196297-77F80D59-F570-4B20-9A4E-F673049D7363Q35567287-2B57463A-F234-4AC8-9EB3-9075AF63855EQ35782562-D8BFABF2-DCFA-432A-BDEB-3D0CE7BFEE8FQ35847659-9A048EEC-54B5-49AA-86DB-67C7E609BC01Q36020057-9C938C29-810D-4B8B-8173-748EACF2BB18Q36052743-830AEAA7-9F33-471C-BB22-9E88AE80B5EAQ36081148-A81FB779-4DCE-4E54-8A01-ACC694D99F3DQ36120816-5BBF1367-B8AC-44F1-9658-E87E23AF701BQ36209913-0C647ED0-A573-4028-A377-F51D51D8FD52Q36250753-4D863389-3592-4E27-90A3-7BE9BBA30395Q36316872-4955258D-40E7-4900-8296-D9F33DCE3A0FQ36489174-A9365D4E-9F6C-4EA8-8780-CB452B5BA5C6Q36572571-195CE3D4-DD09-49E3-AB8E-794B9E1F2675Q36624060-86DF0BBE-5D27-45C1-BBCE-10C2E05EA7A7Q36935258-A435B30E-12C4-4B22-B428-7E0F0F7ABF15
P2860
Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Reversal of resistance by GF12 ...... the ABC half-transporter, MXR.
@en
Reversal of resistance by GF12 ...... the ABC half-transporter, MXR.
@nl
type
label
Reversal of resistance by GF12 ...... the ABC half-transporter, MXR.
@en
Reversal of resistance by GF12 ...... the ABC half-transporter, MXR.
@nl
prefLabel
Reversal of resistance by GF12 ...... the ABC half-transporter, MXR.
@en
Reversal of resistance by GF12 ...... the ABC half-transporter, MXR.
@nl
P2093
P1433
P1476
Reversal of resistance by GF12 ...... the ABC half-transporter, MXR.
@en
P2093
P304
P356
10.1016/S0304-3835(99)00182-2
P407
P577
1999-11-01T00:00:00Z